The positive Part 2 data de-risks the obefazimod program ahead of NDA submission in Q4 2026. Traders should monitor for regulatory updates, potential partnership announcements, and the H1 2026 financial results on September 21, 2026. The stock may see upward momentum, but given prior volatility, consider taking profits on strength.
Price Chart
Executive Summary
Abivax reported positive topline results from Part 2 of the Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, showing clinically meaningful efficacy in refractory patients (37.2% clinical remission at 50 mg in induction non-responders) and a safety profile with malignancy rates within UC background ranges. The company remains on track for NDA submission in Q4 2026, strengthening the drug's regulatory path.
Key Facts
- 50 mg obefazimod achieved 37.2% clinical remission, 61.5% clinical response, 48.0% endoscopic improvement, 44.6% HEMI, and 34.5% endoscopic remission in induction non-responders at Week 44.
- Part 1 relapsers re-treated with 50 mg obefazimod achieved 45.0% clinical remission (placebo→50 mg) and 45.5% (25 mg→50 mg).
- Exposure-adjusted incidence rate (EAIR) for malignancies excluding NMSC in the integrated UC program (all active) was 0.35 per 100 PY, within the UC background range of 0.30–0.70.
- EAIR for NMSC in the integrated program (all active) was 0.59 per 100 PY, within the UC background range of 0.70–1.40.
- No new safety signals emerged; NDA submission remains on track for Q4 2026.
Financial Impact
Positive catalyst for ABVX stock; strengthens probability of NDA approval and potential commercial launch. No financial figures provided in the filing.
Risk Factors
- Regulatory risk: FDA may require additional data or raise concerns about safety or efficacy.
- Competition from existing and emerging UC therapies (e.g., JAK inhibitors, anti-integrins).
- Financing risk: Abivax may need to raise capital to fund commercialization and ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-288752 |
| Document: d110874dex991.htm | 0001193125-26-288752 |
| Document: 0001193125-26-288752-index-headers.html | 0001193125-26-288752 |
| Document: 0001193125-26-288752-index.html | 0001193125-26-288752 |
| Document: 0001193125-26-288752.txt | 0001193125-26-288752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | $94.17 (−27.56%) |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | $94.17 (+28.96%) |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | $94.17 (−25.50%) |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | $94.17 (−14.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access